Improved antitumor efficacy of neutrophils stimulated by bacillus Calmette‑Guérin

  • Authors:
    • Huan Wang
    • Danan Wang
    • Yonghui Feng
    • Jingbo Zhai
    • Changlong Lu
  • View Affiliations

  • Published online on: July 25, 2019     https://doi.org/10.3892/mmr.2019.10532
  • Pages: 2909-2915
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bacillus Calmette‑Guérin (BCG) has become a significant treatment for bladder cancer, and neutrophils are reported to be associated with the antitumor effect of BCG. The aim of the present study was to clarify the antitumor function of neutrophils stimulated by BCG. Initially, the killing effect and cytotoxic activity of neutrophils treated with BCG was detected. Subsequently, the effectiveness of BCG‑treated neutrophils extracted from tumor‑bearing mice was analyzed. The results revealed that the cytotoxic effect of neutrophils was stronger in the BCG‑treated group compared with that in the normal saline (NS)‑treated and control groups (P<0.05). A significantly higher concentration of cytokines tumor necrosis factor (TNF)‑α, interleukin (IL)‑1β, IL‑6 and TNF‑related apoptosis‑inducing ligand occurred in the BCG‑treated neutrophil group compared with the NS and control groups (P<0.01), which was also associated with the BCG dose (P<0.01). The gross tumor volume percentage in BCG‑treated neutrophils from tumor‑bearing mice (BCGT group) was significantly lower in comparison with that in the NS‑treated neutrophils from tumor‑bearing mice (NST group; P<0.05). In addition, the survival rate of tumor‑bearing mice was higher in the BCGT group compared with the NST group (P<0.05), while more BCG‑treated neutrophils from tumor‑bearing mice were infiltrated in the MethA tumor (P<0.01). In conclusion, BCG‑treated neutrophils were observed to enhance the antitumor efficacy and extend the life span of mice.

References

1 

Spencer BA, McBride RB, Hershman DL, Buono D, Herr HW, Benson MC, Guptamohile S and Neugut AI: Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract. 9:92–98. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Kawai K, Miyazaki J, Joraku A, Nishiyama H and Akaza H: Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 104:22–27. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, Debois H, Abbou CC and Chopin DK: Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology. 57:617–622. 2001. View Article : Google Scholar : PubMed/NCBI

4 

Ermert D, Niemiec MJ, Röhm M, Glenthøj A, Borregaard N and Urban CF: Candida albicans escapes from mouse neutrophils. J Leukoc Biol. 94:223–236. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Koga Y, Matsuzaki A, Suminoe A, Hattori H and Hara T: Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): A novel mechanism of antitumor effect by neutrophils. Cancer Res. 64:1037–1043. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Antony VB, Sahn SA, Antony AC and Repine JE: Bacillus Calmette-Guérin-stimulated neutrophils release chemotaxins for monocytes in rabbit pleural spaces and in vitro. J Clin Invest. 76:1514–1521. 1985. View Article : Google Scholar : PubMed/NCBI

7 

Moliva JI, Turner J and Torrelles JB: Immune responses to bacillus Calmette-Guérin vaccination: Why do they fail to protect against Mycobacterium tuberculosis? Front Immunol. 8:4072017. View Article : Google Scholar : PubMed/NCBI

8 

Rosevear HM, Lightfoot AJ, O'Donnell MA and Griffith TS: The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev. 28:345–353. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, et al: Transterable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA. 103:7753–7758. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Cui Z, Willingham MC, Hicks AM, Alexandermiller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W and DeLong CJ: Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA. 100:6682–6687. 2003. View Article : Google Scholar : PubMed/NCBI

11 

Souto JC, Vila L and Brú A: Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev. 31:311–363. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stöckle M, Jocham D, Böhle A and Brandau S: Neutrophil granulocytes are required for effective bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66:8250–8257. 2006. View Article : Google Scholar : PubMed/NCBI

13 

De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, Van der Meijden AP, Vegt PD, Debruyne FM and Ruitenberg EJ: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother. 34:306–312. 1992. View Article : Google Scholar : PubMed/NCBI

14 

de Boer EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH and Schamhart DH: Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res. 25:31–34. 1997. View Article : Google Scholar : PubMed/NCBI

15 

Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C and Kieber-Emmons T: Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int J Mol Med. 17:1045–1052. 2006.PubMed/NCBI

16 

Yoshie O, Aso H, Nanjo M, Tamura K, Ebina T and Ishida N: Antitumor effect of recombinant human interferon alpha A/D on Meth-A sarcoma in mice. Jpn J Cancer Res. 77:413–418. 1986.PubMed/NCBI

17 

Huntington ND, Vosshenrich CA and Di Santo JP: Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 7:703–714. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Kim JM, Kim JS, Jung HC, Song IS and Kim CY: Apoptosis of human gastric epithelial cells via caspase-3 activation in response to Helicobacter pylori infection: Possible involvement of neutrophils through tumor necrosis factor alpha and soluble Fas ligands. Scand J Gastroenterol. 35:40–48. 2000. View Article : Google Scholar : PubMed/NCBI

19 

Bisiaux A, Boussier J, Duffy D, Quintana-Murci L, Fontes M and Albert ML; Milieu Intérieur Consortium, : Deconvolution of the response to bacillus Calmette-Guérin reveals NF-κB-induced cytokines as autocrine mediators of innate immunity. Front Immunol. 8:7962017. View Article : Google Scholar : PubMed/NCBI

20 

Queiroz DM, Guerra JB, Rocha GA, Rocha AM, Santos A, De Oliveira AG, Cabral MM, Nogueira AM and De Oliveira CA: IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Gastroenterology. 127:73–79. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K and Yagita H: Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol. 162:2639–2647. 1999.PubMed/NCBI

22 

Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K and Yagita H: Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human t cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med. 189:1451–1460. 1999. View Article : Google Scholar : PubMed/NCBI

23 

Mariani SM and Krammer PH: Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol. 28:1492–1498. 1998. View Article : Google Scholar : PubMed/NCBI

24 

Kashii Y, Giorda R, Herberman RB, Whiteside TL and Vujanovic NL: Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol. 163:5358–5366. 1999.PubMed/NCBI

25 

Fanger NA, Maliszewski CR, Schooley K and Griffith TS: Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med. 190:1155–1164. 1999. View Article : Google Scholar : PubMed/NCBI

26 

Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR and Fanger NA: Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 189:1343–1354. 1999. View Article : Google Scholar : PubMed/NCBI

27 

Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, Bingle CD, Chilvers ER and Whyte MK: Acceleration of human neutrophil apoptosis by TRAIL. J Immunol. 170:1027–1033. 2003. View Article : Google Scholar : PubMed/NCBI

28 

Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA and Griffith TS: Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 64:3386–3390. 2004. View Article : Google Scholar : PubMed/NCBI

29 

Morales A, Eidinger D and Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 116:180–183. 1976. View Article : Google Scholar : PubMed/NCBI

30 

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al: Mutational landscape and significance across 12 major cancer types. Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Kusumanto YH, Dam WA, Hospers GA, Meijer C and Mulder NH: Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 6:283–287. 2003. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, H., Wang, D., Feng, Y., Zhai, J., & Lu, C. (2019). Improved antitumor efficacy of neutrophils stimulated by bacillus Calmette‑Guérin. Molecular Medicine Reports, 20, 2909-2915. https://doi.org/10.3892/mmr.2019.10532
MLA
Wang, H., Wang, D., Feng, Y., Zhai, J., Lu, C."Improved antitumor efficacy of neutrophils stimulated by bacillus Calmette‑Guérin". Molecular Medicine Reports 20.3 (2019): 2909-2915.
Chicago
Wang, H., Wang, D., Feng, Y., Zhai, J., Lu, C."Improved antitumor efficacy of neutrophils stimulated by bacillus Calmette‑Guérin". Molecular Medicine Reports 20, no. 3 (2019): 2909-2915. https://doi.org/10.3892/mmr.2019.10532